Zogenix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZGNX research report →
About the company
Zogenix, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for rare diseases within the United States, striving to profoundly improve the quality of life for affected patients and their families. Their flagship product candidate, Fintepla, a low-dose fenfluramine, is currently undergoing Phase III clinical evaluation for the management of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.
- CEO
- Stephen Farr
- IPO
- 2010
- Employees
- 327
- HQ
- Emeryville, CA, US
Price Chart
- Market Cap
- $0
- P/E
- -6.29
- P/S
- 0.00
- P/B
- 8.00
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
- Gross Margin
- 94.08%
- Op Margin
- -259.56%
- Net Margin
- -278.39%
- ROE
- -82.90%
- ROIC
- -56.92%
- Revenue
- $81.69M · 498.77%
- Net Income
- $-227,413,000 · -8.61%
- EPS
- $-4.24 · -8.72%
- Op Income
- $-212,032,000
- FCF YoY
- -3.62%
- 52W High
- $26.90
- 52W Low
- $11.03
- 50D MA
- $23.18
- 200D MA
- $17.40
- Beta
- 0.90
- Avg Volume
- 3.10M
Get TickerSpark's AI analysis on ZGNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 7, 22 | BREITMEYER JAMES B | sell | 6,250 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 20,000 |
| Mar 7, 22 | BREITMEYER JAMES B | other | 1,250 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 9,375 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 10,000 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 22,000 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 9,000 |
| Mar 7, 22 | Stutts Mary E. | sell | 22,000 |
| Mar 7, 22 | Stutts Mary E. | sell | 20,000 |
| Mar 7, 22 | BOCK LOUIS C | sell | 20,000 |
Our ZGNX coverage
Recent articles, reports, and earnings notes.
No research on ZGNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZGNX report →Similar companies
Peers in the same neighborhood.